Technology
Health
Pharmaceutical

Ampio Pharmaceuticals

$0.52
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.0026 (-0.50%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell AMPE and other stocks, options, ETFs, and crypto commission-free!

About

Ampio Pharmaceuticals, Inc, also called Ampio Pharmaceuticals, is a biopharmaceutical company, that engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation, sexual dysfunction and CNS disease. Read More The company was founded by David Bar-Or in April 2010 and is headquartered in Englewood, CO.

Employees
22
Headquarters
Englewood, Colorado
Founded
2010
Market Cap
57.79M
Price-Earnings Ratio
6.95
Dividend Yield
0.00
Average Volume
1.28M
High Today
$0.5298
Low Today
$0.5001
Open Price
$0.5293
Volume
82.23K
52 Week High
$3.20
52 Week Low
$0.3511

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
US
North America

News

Seeking AlphaApr 29

Ampio not quite there with confirmatory study of Ampion; shares down 5% premarket

Nano cap Ampio Pharmaceuticals (NYSEMKT:AMPE) slips 5% premarket on light volume in reaction to its announcement that the FDA does not want it to start its confirmatory trial of Ampion in patients with knee osteoarthritis without the agency's agreement on the trial design.

666
Yahoo FinanceApr 29

Ampio Pharmaceuticals Provides Regulatory Update

ENGLEWOOD, Colo., April 29, 2019 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has received comments from the U.S. Food and Drug Administration (FDA) regarding their Special Protocol Assessment (SPA). The FDA recommended the Company not start their confirmatory trial without obtaining FDA concurrence on the trial design. The Company agreed with the comments they received from the FDA and immediately sent a revised SPA to the FDA for review. Ampio Pharmaceuticals Logo....

230

Earnings

Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
Actual
Expected May 13, After Hours

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.